Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07143604 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2

Study acronym: GAMBIT
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date changed from estimate of Sep 28, 2026 to Aug 14, 2026 Eligibility criteria expanded, about 14 words · Secondary endpoints: details revised at 3 of 6 entries Show 2 more changesShow less
    • Eligibility criteria expanded, about 14 words
    • Secondary endpoints: details revised at 3 of 6 entries
  2. Re-verified, no change to tracked fieldsv8
  3. Trial status: Recruiting to Active, Not Recruiting Study sites: 14 to 13v7 Show 1 more changeShow less
    • Study sites: 14 to 13
  4. Re-verified, no change to tracked fieldsv6
  5. Study sites: 13 to 14v5
Show 3 earlier versionsHide 3 earlier versions
  1. Site details revised at 9 of 13 sitesv4
  2. Site details revised at 7 of 13 sitesv3
  3. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Aug 25, 2025 to Aug 29, 2025 · Site details revised at 13 of 13 sitesv2 Show 2 more changesShow less
    • Start date changed from estimate of Aug 25, 2025 to Aug 29, 2025
    • Site details revised at 13 of 13 sites
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
727 trials monitored
See 61 trials at risk
Gastric Cancer
1,201 trials monitored
See 59 trials at risk
The purpose of this study is to measure the efficacy and safety of AZD0901 monotherapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.
Trial Details
NCT Number NCT07143604
Lead Sponsor AstraZeneca
Conditions Gastric Cancer, Gastroesophageal Junction Cancer
Enrollment 33 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov